

MAR 20 2002

**REVISED**



**BD**

Indispensable to  
human health

## **Summary of Safety and Effectiveness for the BD Bifurcated Needle**

**1 BD Contact person:**

Pasquale Amato  
Regulatory Affairs Coordinator  
BD Medical Surgical – Mail Code 226  
1 Becton Drive  
Franklin Lakes, NJ 07417-1880  
Phone (201) 847- 4513  
Fax (201) 847- 4855

Device Name: BD Bifurcated Needle

**2 Predicate Device(s):**

- 2.1 Precision Medical Products - K012515
- 2.2 BD Vacutainer® Brand Blood Collection Needle - Pre-Amendment

**3 Product Description / Function:**

Product sizes/reorder numbers:  
The BD Bifurcated Needle will be offered in the following reorder numbers:  
301754; 301755; 301756; 301757.

Intended Uses: The BD Bifurcated needle is intended for use in administering vaccines by the scarification method or administering epidermal allergens.

**4 Equivalence determination:**

The elements of comparison between the BD Bifurcated Needle and the Precision Medical Products predicate device are as follows:

Labeling: The performance claims on the BD Bifurcated needle are equivalent to those of the predicated device, i.e.:

- ☐ Intended use
- ☐ Single use
- ☐ Sterile (including statement on package integrity)
- ☐ Package open instruction



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAR 20 2002

Mr. Pasquale Amato  
Regulatory Affairs Coordinator  
BD Medical Surgical  
One Becton Drive MC226  
Franklin Lakes, New Jersey 07417

Re: K020523  
Trade/Device Name: BD Bifurcated Needle  
Regulation Number: None  
Regulation Name: Bifurcated Needle  
Regulatory Class: Unclassified  
Product Code: LDH  
Dated: February 15, 2002  
Received: February 19, 2002

Dear Mr. Amato:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Timothy A. Ulatowski

Director

Division of Dental, Infection Control  
and General Hospital Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

## REVISED

### Indications for Use

The BD Bifurcated needle is intended for use in administering vaccines by the scarification method or administering epidermal allergens.

*Patricia Cascone*  
(Division Sign-Off)  
Division of Dental, Infection Control,  
and General Hospital Devices  
510(k) Number K020523